Abstract

The present invention relates to methods of using CCR1 antagonists as immunomodulatory agents. In particular, the present invention relates to methods of using heteroaryl-hexanoic acid amide derivatives of the formula (I)



(I)

wherein R^1, R^2, R^3, and Y are as described in the specification.